Meningococcal serogroup C-specific IgG antibody responses and serum bactericidal titres in children following vaccination with a meningococcal A/C polysaccharide vaccine

Borrow, Ray

doi:10.1016/s0928-8244(00)00136-x

Cited by 13 publications

(16 citation statements)

References 22 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is also supported by the vaccine effectiveness reported following a mass immunization campaign against menC disease in Quebec, where the effectiveness was 41% for ages 2 to 9 years (12). Our data for menC are also similar to those reported in a previous study of bivalent polysaccharide in young children in the United Kingdom (10). A small French study performed with older children (ages, 3 to 13 years) and with a single dose of tetravalent polysaccharide demonstrated that all 21 children responded, as measured by a Նfourfold increase in the SBA titer pre-to post vaccination for all four serogroups (11).…”

Section: Discussionsupporting

confidence: 89%

Serologic Responses to ACYW135 Polysaccharide Meningococcal Vaccine in Saudi Children under 5 Years of Age

et al. 2005

View full text Add to dashboard Cite

An immunization campaign with meningococcal ACYW135 polysaccharide vaccine was conducted in 2003 by the Saudi Arabian Ministry of Health and included a study to evaluate the immune responses in children under 5 years of age in the Al Qassim region of Saudi Arabia. Children who were >24 months old were given one dose of tetravalent polysaccharide vaccine, while younger children were given two doses with an interval of 2 to 3 months. Blood samples were collected prevaccination and 1 month after the second dose for children younger than 24 months old and 1 month after the single dose for older children. Serogroup-specific antibody responses were determined by serum bactericidal antibody (SBA) assays and a tetraplex immunoglobulin G (IgG) bead assay. Significant increases in the proportions of individuals who were >24 months old with SBA titers of >8 were observed pre-to postvaccination for all serogroups. Age-dependent increases in the percentage of individuals with SBA titers of >8 1 month postvaccination were observed for each serogroup. Age-dependent increases in postvaccination IgG levels were observed for serogroup A (menA), serogroup W135 (menW), and serogroup Y (menY) but not for serogroup C (menC). Two doses of tetravalent polysaccharide vaccine in individuals who were <18 months old were poorly immunogenic for menC, menW, and menY. However, for menA, 42% of the children who were 18 months old were putatively protected with SBA titers of >8. A high percentage of subjects who were >2 years of age were putatively protected for menA; a similar level was observed for menY for children who were 4 years of age but not for younger children. However, for menC and menW poor levels of putative protection were still evident at 4 years of age.

show abstract

Section: Discussionsupporting

confidence: 89%

Serologic Responses to ACYW135 Polysaccharide Meningococcal Vaccine in Saudi Children under 5 Years of Age

et al. 2005

View full text Add to dashboard Cite

show abstract

“…The SBA response to the booster MCC-TT vaccine was higher than the response to primary immunization and the response in naive toddlers receiving MCC-TT vaccine at this age (27a). The antibody response to the booster MACP vaccine was greater than in naive children given this vaccine (7,20,22), confirming the successful induction of immunologic memory. The presence of memory is sufficient for long-term protection following administration of Hib conjugate vaccines (5,28) and is expected to be sufficient after administration of MCC vaccines, although the high incidence of MenC disease in adolescence (25) means that a longer duration of protection is required.…”

Section: Discussionmentioning

confidence: 60%

“…Sera were tested using standardized complement-mediated serum bactericidal assays against three MenC strains described previously (7,26). The complement source was pooled baby rabbit serum (Pelfreeze Biologicals).…”

Section: Methodsmentioning

confidence: 99%

Evaluation of De-O-Acetylated Meningococcal C Polysaccharide-Tetanus Toxoid Conjugate Vaccine in Infancy: Reactogenicity, Immunogenicity, Immunologic Priming, and Bactericidal Activity against O-Acetylated and De-O-Acetylated Serogroup C Strains

et al. 2001

View full text Add to dashboard Cite

“…For toddlers with a postprimary SBA titer of Ͻ128, 90% had a postbooster titer of Ն128, compared with only 8% of age-matched naïve controls given a full 50-g dose of C polysaccharide (8). This difference in response confirms the induction of immunological memory in the MCC vaccines despite postprimary SBA antibody levels in the equivocal range.…”

Section: Discussionmentioning

confidence: 70%

Serological Basis for Use of Meningococcal Serogroup C Conjugate Vaccines in the United Kingdom: Reevaluation of Correlates of Protection

Borrow

Andrews²,

Miller³

2001

Infect Immun

297

194

View full text Add to dashboard Cite

The antibody data supporting the use of meningococcal serogroup C conjugate (MCC) vaccines in the United Kingdom were generated by serum bactericidal assay (SBA) using rabbit complement (rSBA). This may give higher titers than those obtained with human complement (hSBA), for which the "gold standard" correlate of protection for meningococcal C disease is a titer of >4. Comparison of rSBA and hSBA titers in sera from unvaccinated adults with an rSBA titer of >8 showed that for 93% (27 of 29) the titer was >4 by hSBA, confirming natural protection. Furthermore, sera from MCC vaccinees showed that an rSBA titer of <8 or >128 discriminated susceptibility and protection well (85% with rSBA titers of <8 had hSBA titers of <4, and 99% with rSBA titers of >128 had hSBA titers of >4). However, discrimination was poor in the rSBA titer range 8 to 64, with only 60% having hSBA titers of >4. In such cases we propose that protection can be assumed if there is a fourfold rise in titer between pre-and postvaccination sera or if there is a characteristic booster response to a polysaccharide challenge dose with, if available, evidence of antibody avidity maturation or an hSBA titer of result >4. Applying these criteria to toddlers, 10 to 40% of whom had titers in the range 8 to 64 after a single dose of MCC vaccine, showed that 94% had a fourfold rise in titer, including 98% of those in the titer range 8 to 64. In addition, of those with titers of <128 post-MCC vaccination, 90% had titers of >128 after a 10-g polysaccharide booster dose, compared with only 7% of unprimed age-matched toddlers given a full 50-g dose. Furthermore, the increase in geometric mean avidity index pre-and postbooster was independent of post-primary MCC titer. These results indicated that the majority of toddlers with an rSBA titer between 8 and 64, and some of those with an hSBA result of <4, have mounted a protective immune response with the induction of immunological memory.

show abstract

Meningococcal serogroup C-specific IgG antibody responses and serum bactericidal titres in children following vaccination with a meningococcal A/C polysaccharide vaccine

Cited by 13 publications

References 22 publications

Serologic Responses to ACYW135 Polysaccharide Meningococcal Vaccine in Saudi Children under 5 Years of Age

Serologic Responses to ACYW135 Polysaccharide Meningococcal Vaccine in Saudi Children under 5 Years of Age

Evaluation of De-O-Acetylated Meningococcal C Polysaccharide-Tetanus Toxoid Conjugate Vaccine in Infancy: Reactogenicity, Immunogenicity, Immunologic Priming, and Bactericidal Activity against O-Acetylated and De-O-Acetylated Serogroup C Strains

Serological Basis for Use of Meningococcal Serogroup C Conjugate Vaccines in the United Kingdom: Reevaluation of Correlates of Protection

Contact Info

Product

Resources

About